Postictal serum levels of antiepileptic drugs for detection of noncompliance

Epilepsy and Behavior

Volumn 4, Issue 5, 2003, Pages 487-495

  Specht, U ^a   Elsner, H ^a   May, T W ^a   Schimichowski, B ^a   Thorbecke, R ^a  

^a EPILEPSY CENTER BETHEL   (Germany)

Author keywords

Antiepileptic drugs; Compliance; Epilepsy; Serum concentration

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; SULTIAME; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; ANTICONVULSANT THERAPY; ARTICLE; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG USE; EPILEPSY; FEMALE; FREQUENCY ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PATIENT COMPLIANCE; PATIENT MONITORING; QUANTITATIVE ANALYSIS; REFERENCE VALUE; RELIABILITY; SEIZURE;

EID: 0242606931     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-5050(03)00151-3     Document Type: Article

References (48)

1. Bryant SG, Ereshefsky L. Determinants of compliance in epileptic outpatients. Drug Intell Clin Pharm 1981;16:572-7.
2. Peterson GM, McLean S, Millingen KS. Determinants of patient compliance with anticonvulsant therapy. Epilepsia 1982;23:607-13.
3. Thorbecke R. Measurement of compliance through patient interviews. In: Schmidt D, Leppik IE, editors. Compliance in epilepsy (Epilepsy Res Suppl 1). Amsterdam: Elsevier Science; 1988. p. 79-83.
4. Buck D, Jacoby A, Baker GA, Chadwick DW. Factors influencing compliance with antiepileptic, drug regimes. Seizure 1997;6:87-93.
5. Kyngäs H. Compliance with health regimens of adolescents with epilepsy. Seizure 2000;9:598-604.
6. Driessen O, Höppener R. Plasma levels of phenobarbital and phenytoin in epileptic outpatients. Eur Neurol 1977;15:135-42.
7. Takaki S, Kurokawa T, Aoyama T. Monitoring drug noncompliance in epileptic patients: assessing phenobarbital plasma levels. Ther Drug Monit 1985;7:87-91.
8. Mattson RH, Cramer JA, Collins JF, the VA Epilepsy Cooperative Study Group. Aspects of compliance: taking drugs and keeping clinic appointments. In: Schmidt D, Leppik IE, editors. Compliance in epilepsy (Epilepsy Res. Suppl 1). Amsterdam: Elsevier Science; 1988, p. 111-7.
9. Leppik IE, Cloyd JC, Sawchuk RJ, Pepin SM. Compliance and variability of plasma phenytoin levels in epileptic patients. Ther Drug Monit 1979;1:475-83.
10. McGlone R, Pritty P. Measuring anti-convulsant levels in the accident and emergency department. Arch Emerg Med 1986;3:141-3.
11. Schmidt D, Reininghaus R, Winkel R. Relevance of poor compliance for seizure control. In: Schmidt D, Leppik IE, editors. Compliance in epilepsy (Epilepsy Res Suppl 1). Amsterdam: Elsevier Science; 1988. p. 141-6.
12. Graves NM, Holmes GB, Leppik IE. Compliant populations: variability in serum concentrations. In: Schmidt D, Leppik IE, editors. Compliance in epilepsy (Epilepsy Res Suppl 1). Amsterdam: Elsevier Science; 1988. p. 91-9.
13. Snodgrass SR, Vedanarayanan V, Parker CC, Parks BR. Pediatric patients with undetectable anticonvulsant blood levels: comparison with compliant patients. J Child Neurol 2001;16:164-8.
14. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-7.
15. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990;150:1509-10.
16. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
17. Rambeck B, May T. Urinary hydroxyphenytoin/creatinine ratios as an index of compliance in adult epileptic patients on phenytoin therapy. Ther Drug Monit 1984;6:164-72.
18. Friedmann IM, Litt IF, King DR, et al. Compliance with anticonvulsant therapy by epileptic youth: relationship to psychosocial aspects of adolescent development. J Adolesc Health Care 1986;7:12-7.
19. Psillakis T, Tsatsakis AM, Christodoulou P, Michalodimitrakis M, Paritsis N, Helidonis E. Carbamazepine levels in head hair of patients under long-term treatment: a method to evaluate the history of drug use. J Clin Pharmacol 1999;39:55-67.
20. Williams J, Myson V, Steward S, et al. Self-discontinuation of antiepileptic medication in pregnancy: detection by hair analysis. Epilepsia 2002;43:824-31.
21. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondary generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51.
22. Cramer JA, Mattson RH. Compliance with antiepileptic drug therapy. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press; 1995. p. 149-59.
23. Leppik IE. Laboratory tests. In: Engel Jr J, Pedley TA, editors. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven; 1997. p. 811-7.
24. Glauser TA, Pippenger CE. Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy. Epilepsia 2000;41(Suppl 8):S6-S15.
25. Commission on Classification and Terminology of the International League against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
26. Commission on Classification and Terminology of the International League against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
27. Commission on Antiepileptic Drugs of the International League against Epilepsy. Guidelines for therapeutic monitoring on antiepileptic drugs. Epilepsia 1993;34:585-7.
28. Jürgens U. HPLC analysis of antiepileptic drugs in blood samples: microbore separation of fourteen compounds. J Liquid Chromatogr 1987;10:507-32.
29. Jürgens U, May TW, Rambeck B. Simultaneous HPLC determination of vigabatrin and gabapentin in serum with automated pre-injection derivatization. J Liquid Chromatogr 1996;19:1459-71.
30. Leppik IE. Variability of phenytoin, carbamazepine and valproate concentrations in a clinic population. In: Schmidt D, Leppik IE, editors. Compliance in epilepsy (Epilepsy Res Suppl 1). Amsterdam: Elsevier Science; 1988. p. 85-90.
31. Williams J, Patsalos PN, Mei Z, Schapel G, WIlson JF, Richens A. Relation between dosage of carbamazepine and concentration in hair and plasma samples from a compliant inpatient epileptic population. Ther Drug Monit 2001;23:15-20.
32. Sundqvist A, Tomson T, Lundkvist B. Pharmacokinetics of valproic acid in patients with juvenile myoclonic epilepsy on monotherapy. Ther Drug Monit 1997;19:153-9.
33. May TW, Rambeck B. Fluctuations of unbound and total phenytoin concentrations during the day in epileptic patients on valproic acid comedication. Ther Drug Monit 1990;12:124-8.
34. Bourgeois BF. Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed? Neurology 2000;55:S11-6.
35. Siegel S, Castellan NJ. Nonparametric statistics. 2nd ed. New York: McGraw-Hill; 1988.
36. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Erlbaum; 1988.
37. Erdfelder E, Faul F, Buchner A. GPOWER: a general power analysis program. Behav Res Methods Instrum Computers 1996;28:1-11.
38. Krumholz A, Grufferman S, Orr ST, Stern BJ. Seizures and seizure care in an emergency department. Epilepsia 1989;30: 175-81.
39. Irving P, Dahma AA, Srinivasan A, Greenwood D. An audit of admissions of patients with epilepsy to a district general hospital. Seizure 1999;8:166-9.
40. Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav 2002;3:338-42.
41. So N, Gotman J. Changes in seizure activity following anticonvulsant drug withdrawal. Neurology 1990;40:407-13.
42. Malow BA, Blaxton TA, Stertz B, Theodore WH. Carbamazepine withdrawal: effects of taper rate on seizure frequency. Neurology 1993;43:2280-4.
43. Keränen T, Reinikainen K, Laulumaa V, Koskela K, Hallikainen E, Riekkinen PJ. Carbamazepine monotherapy versus polytherapy in chronic epilepsy. Acta Neurol Scand 1982;(Suppl 90):190.
44. Wilder BJ, Karas BJ, Hammond EJ, Perchalski RJ. Twice-daily dosing of valproate with divalproex. Clin Pharmacol Ther 1983;34:501-4.
45. Sherwin AL, Robb JP, Lechter M. Improved control of epilepsy by monitoring plasma ethosuximide. Arch Neurol 1973;28: 178-81.
46. Shope JT. Compliance in children and adults: review of studies. Epilepsy Res Suppl 1988;1:23-47.
47. Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens. Drugs 1995;49:321-7.
48. Cramer JA, Rosenheck R. Enhancing medication compliance for people with serious mental illness. J Nerv Ment Dis 1999;187: 53-5.